FOCM Virtual Meeting Minutes
Date April 23, 2020
7:00 p.m. – 8:00 p.m.
Kate Mullis (tried)
The meeting was called to order at precisely 7:00 p.m. consistent with FOCM SOPs. If there’s one thing that FOCM stands for it’s being on time. No, no, that’s actually not true. If there’s one thing FOCM stands for its socializing/networking.
The meeting was held via Zoom which I’m not familiar with using, such that when Kate Mullis tried to join, I didn’t notice the “Kate Mullis wants in, do you admit her or not” and she had to give up and put children to bed. FOCM’s chairman vows to do better in the future.
It appears we’re all bearing up under the COVID-19 distancing and limited opportunities for going out other than walks, exercise, picking up take out, following the arrows at the grocery stores. There’s a definite reduction in new study start ups, but a lot of work and planning for how to handle ongoing clinical trials. Decisions on new hiring are also delayed considerably.
Will the future of clinical trials be: a return to the way we were doing them with a gradual move toward reducing patient and site burden or will this be the disruption needed to make virtual/hybrid trials the new normal?
Continue washing your hands and staying away from people. I think based on my review of the data, bar graphs, the number of patients in clinical trials and the early reports finding beneficial effects from some of them that by May 8, we’ll be down to under 10,000 daily new cases.